It is widely accepted that oncogenic KRAS is conductive to promote cell survival, proliferation, and cytokine secretion to acting on stromal cells to promote cancer malignancy by activating intracellular PI3K, MAPK, or RAL‐GEF pathways.32 The gene discussed is RALA; the disease is cancer.